Overview of vaccines and vaccination
Identifieur interne : 001151 ( Istex/Corpus ); précédent : 001150; suivant : 001152Overview of vaccines and vaccination
Auteurs : Gordon AdaSource :
- Molecular Biotechnology [ 1073-6085 ] ; 2005-03-01.
English descriptors
Abstract
Abstract: Of the 80-plus known infectious agents pathogenic for humans, there are now more than 30 vaccines against 26 mainly viral and bacterial infections and these greatly minimize subsequent disease and prevent death after exposure to those agents. This article describes the nature of the vaccines, from live attenuated agents to subunits, their efficacy and safety, and the kind of the immune responses generated by those vaccines, which are so effective. To date, all licensed vaccines generate especially specific antibodies, which attach to the infectious agent and therefore can very largely prevent infection. These vaccines have been so effective in developed countries in preventing mortality after a subsequent infection that attempts are being made to develop vaccines against many of the remaining infectious agents. Many of the latter are difficult to manipulate; they can cause persisting infections or show great antigenic variation. A range of new approaches to improve selected immune responses, such as immunization with DNA or chimeric live vectors, viral or bacterial, are under intense scrutiny, as well as genomic analysis of the agent.
Url:
DOI: 10.1385/MB:29:3:255
Links to Exploration step
ISTEX:55176E01945B709336393E38E36BA1A313B4A8DELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Overview of vaccines and vaccination</title><author><name sortKey="Ada, Gordon" sort="Ada, Gordon" uniqKey="Ada G" first="Gordon" last="Ada">Gordon Ada</name><affiliation><mods:affiliation>Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, 2601, Canberra, ACT, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: gordon.ada@anu.edu.au</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:55176E01945B709336393E38E36BA1A313B4A8DE</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1385/MB:29:3:255</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-94QG2FR8-D/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001151</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001151</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Overview of vaccines and vaccination</title><author><name sortKey="Ada, Gordon" sort="Ada, Gordon" uniqKey="Ada G" first="Gordon" last="Ada">Gordon Ada</name><affiliation><mods:affiliation>Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, 2601, Canberra, ACT, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: gordon.ada@anu.edu.au</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Molecular Biotechnology</title><title level="j" type="abbrev">Mol Biotechnol</title><idno type="ISSN">1073-6085</idno><idno type="eISSN">1559-0305</idno><imprint><publisher>Humana Press</publisher><pubPlace>Totowa</pubPlace><date type="published" when="2005-03-01">2005-03-01</date><biblScope unit="volume">29</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="255">255</biblScope><biblScope unit="page" to="271">271</biblScope></imprint><idno type="ISSN">1073-6085</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1073-6085</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Vaccines</term><term>emerging diseases</term><term>immune responses</term><term>infectious agents</term><term>vaccination</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Of the 80-plus known infectious agents pathogenic for humans, there are now more than 30 vaccines against 26 mainly viral and bacterial infections and these greatly minimize subsequent disease and prevent death after exposure to those agents. This article describes the nature of the vaccines, from live attenuated agents to subunits, their efficacy and safety, and the kind of the immune responses generated by those vaccines, which are so effective. To date, all licensed vaccines generate especially specific antibodies, which attach to the infectious agent and therefore can very largely prevent infection. These vaccines have been so effective in developed countries in preventing mortality after a subsequent infection that attempts are being made to develop vaccines against many of the remaining infectious agents. Many of the latter are difficult to manipulate; they can cause persisting infections or show great antigenic variation. A range of new approaches to improve selected immune responses, such as immunization with DNA or chimeric live vectors, viral or bacterial, are under intense scrutiny, as well as genomic analysis of the agent.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>Gordon Ada</name><affiliations><json:string>Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, 2601, Canberra, ACT, Australia</json:string><json:string>E-mail: gordon.ada@anu.edu.au</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Vaccines</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>vaccination</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>infectious agents</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>immune responses</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>emerging diseases</value></json:item></subject><articleId><json:string>293255</json:string><json:string>Art293255</json:string></articleId><arkIstex>ark:/67375/VQC-94QG2FR8-D</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>ReviewPaper</json:string></originalGenre><abstract>Abstract: Of the 80-plus known infectious agents pathogenic for humans, there are now more than 30 vaccines against 26 mainly viral and bacterial infections and these greatly minimize subsequent disease and prevent death after exposure to those agents. This article describes the nature of the vaccines, from live attenuated agents to subunits, their efficacy and safety, and the kind of the immune responses generated by those vaccines, which are so effective. To date, all licensed vaccines generate especially specific antibodies, which attach to the infectious agent and therefore can very largely prevent infection. These vaccines have been so effective in developed countries in preventing mortality after a subsequent infection that attempts are being made to develop vaccines against many of the remaining infectious agents. Many of the latter are difficult to manipulate; they can cause persisting infections or show great antigenic variation. A range of new approaches to improve selected immune responses, such as immunization with DNA or chimeric live vectors, viral or bacterial, are under intense scrutiny, as well as genomic analysis of the agent.</abstract><qualityIndicators><score>9.112</score><pdfWordCount>8783</pdfWordCount><pdfCharCount>56059</pdfCharCount><pdfVersion>1.5</pdfVersion><pdfPageCount>17</pdfPageCount><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>176</abstractWordCount><abstractCharCount>1162</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Overview of vaccines and vaccination</title><genre><json:string>review-article</json:string></genre><host><title>Molecular Biotechnology</title><language><json:string>unknown</json:string></language><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><issn><json:string>1073-6085</json:string></issn><eissn><json:string>1559-0305</json:string></eissn><journalId><json:string>12033</json:string></journalId><volume>29</volume><issue>3</issue><pages><first>255</first><last>271</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Neurosciences</value></json:item><json:item><value>Neurology</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-94QG2FR8-D</json:string></ark><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1385/MB:29:3:255</json:string></doi><id>55176E01945B709336393E38E36BA1A313B4A8DE</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-94QG2FR8-D/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-94QG2FR8-D/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-94QG2FR8-D/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Overview of vaccines and vaccination</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Humana Press</publisher><pubPlace>Totowa</pubPlace><availability><licence><p>Humana Press Inc, 2005</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>2005</date></publicationStmt><notesStmt><note type="review-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Review</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Overview of vaccines and vaccination</title><author xml:id="author-0000" corresp="yes"><persName><forename type="first">Gordon</forename><surname>Ada</surname></persName><email>gordon.ada@anu.edu.au</email><affiliation>Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, 2601, Canberra, ACT, Australia</affiliation></author><idno type="istex">55176E01945B709336393E38E36BA1A313B4A8DE</idno><idno type="ark">ark:/67375/VQC-94QG2FR8-D</idno><idno type="DOI">10.1385/MB:29:3:255</idno><idno type="article-id">293255</idno><idno type="article-id">Art293255</idno></analytic><monogr><title level="j">Molecular Biotechnology</title><title level="j" type="abbrev">Mol Biotechnol</title><idno type="pISSN">1073-6085</idno><idno type="eISSN">1559-0305</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">10</idno><idno type="volume-issue-count">3</idno><imprint><publisher>Humana Press</publisher><pubPlace>Totowa</pubPlace><date type="published" when="2005-03-01"></date><biblScope unit="volume">29</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="255">255</biblScope><biblScope unit="page" to="271">271</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2005</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Of the 80-plus known infectious agents pathogenic for humans, there are now more than 30 vaccines against 26 mainly viral and bacterial infections and these greatly minimize subsequent disease and prevent death after exposure to those agents. This article describes the nature of the vaccines, from live attenuated agents to subunits, their efficacy and safety, and the kind of the immune responses generated by those vaccines, which are so effective. To date, all licensed vaccines generate especially specific antibodies, which attach to the infectious agent and therefore can very largely prevent infection. These vaccines have been so effective in developed countries in preventing mortality after a subsequent infection that attempts are being made to develop vaccines against many of the remaining infectious agents. Many of the latter are difficult to manipulate; they can cause persisting infections or show great antigenic variation. A range of new approaches to improve selected immune responses, such as immunization with DNA or chimeric live vectors, viral or bacterial, are under intense scrutiny, as well as genomic analysis of the agent.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Index Entries</head><item><term>Vaccines</term></item><item><term>vaccination</term></item><item><term>infectious agents</term></item><item><term>immune responses</term></item><item><term>emerging diseases</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Biomedicine</head><item><term>Neurosciences</term></item><item><term>Neurology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2005-03-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-94QG2FR8-D/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Humana Press</PublisherName><PublisherLocation>Totowa</PublisherLocation></PublisherInfo><Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>12033</JournalID><JournalPrintISSN>1073-6085</JournalPrintISSN><JournalElectronicISSN>1559-0305</JournalElectronicISSN><JournalTitle>Molecular Biotechnology</JournalTitle><JournalAbbreviatedTitle>Mol Biotechnol</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Biomedicine</JournalSubject><JournalSubject Type="Secondary">Neurosciences</JournalSubject><JournalSubject Type="Secondary">Neurology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>29</VolumeIDStart><VolumeIDEnd>29</VolumeIDEnd><VolumeIssueCount>3</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular"><IssueInfo TocLevels="0"><IssueIDStart>3</IssueIDStart><IssueIDEnd>3</IssueIDEnd><IssueArticleCount>10</IssueArticleCount><IssueHistory><CoverDate><Year>2005</Year><Month>3</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>Humana Press Inc.</CopyrightHolderName><CopyrightYear>2005</CopyrightYear></IssueCopyright></IssueInfo><Article ID="Art293255"><ArticleInfo ArticleType="ReviewPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>293255</ArticleID><ArticleDOI>10.1385/MB:29:3:255</ArticleDOI><ArticleSequenceNumber>8</ArticleSequenceNumber><ArticleTitle Language="En">Overview of vaccines and vaccination</ArticleTitle><ArticleCategory>Review</ArticleCategory><ArticleFirstPage>255</ArticleFirstPage><ArticleLastPage>271</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2007</Year><Month>6</Month><Day>6</Day></RegistrationDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>Humana Press Inc</CopyrightHolderName><CopyrightYear>2005</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants><ArticleContext><JournalID>12033</JournalID><VolumeIDStart>29</VolumeIDStart><VolumeIDEnd>29</VolumeIDEnd><IssueIDStart>3</IssueIDStart><IssueIDEnd>3</IssueIDEnd></ArticleContext></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Gordon</GivenName><FamilyName>Ada</FamilyName></AuthorName><Contact><Email>gordon.ada@anu.edu.au</Email></Contact></Author><Affiliation ID="Aff1"><OrgDivision>Division of Immunology and Genetics, John Curtin School of Medical Research</OrgDivision><OrgName>Australian National University</OrgName><OrgAddress><Postcode>2601</Postcode><City>Canberra</City><State>ACT</State><Country>Australia</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Abstract</Heading><Para>Of the 80-plus known infectious agents pathogenic for humans, there are now more than 30 vaccines against 26 mainly viral and bacterial infections and these greatly minimize subsequent disease and prevent death after exposure to those agents. This article describes the nature of the vaccines, from live attenuated agents to subunits, their efficacy and safety, and the kind of the immune responses generated by those vaccines, which are so effective. To date, all licensed vaccines generate especially specific antibodies, which attach to the infectious agent and therefore can very largely prevent infection. These vaccines have been so effective in developed countries in preventing mortality after a subsequent infection that attempts are being made to develop vaccines against many of the remaining infectious agents. Many of the latter are difficult to manipulate; they can cause persisting infections or show great antigenic variation. A range of new approaches to improve selected immune responses, such as immunization with DNA or chimeric live vectors, viral or bacterial, are under intense scrutiny, as well as genomic analysis of the agent.</Para></Abstract><KeywordGroup Language="En"><Heading>Index Entries</Heading><Keyword>Vaccines</Keyword><Keyword>vaccination</Keyword><Keyword>infectious agents</Keyword><Keyword>immune responses</Keyword><Keyword>emerging diseases</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Overview of vaccines and vaccination</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Overview of vaccines and vaccination</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Gordon</namePart><namePart type="family">Ada</namePart><affiliation>Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, 2601, Canberra, ACT, Australia</affiliation><affiliation>E-mail: gordon.ada@anu.edu.au</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="ReviewPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>Humana Press</publisher><place><placeTerm type="text">Totowa</placeTerm></place><dateIssued encoding="w3cdtf">2005-03-01</dateIssued><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Abstract: Of the 80-plus known infectious agents pathogenic for humans, there are now more than 30 vaccines against 26 mainly viral and bacterial infections and these greatly minimize subsequent disease and prevent death after exposure to those agents. This article describes the nature of the vaccines, from live attenuated agents to subunits, their efficacy and safety, and the kind of the immune responses generated by those vaccines, which are so effective. To date, all licensed vaccines generate especially specific antibodies, which attach to the infectious agent and therefore can very largely prevent infection. These vaccines have been so effective in developed countries in preventing mortality after a subsequent infection that attempts are being made to develop vaccines against many of the remaining infectious agents. Many of the latter are difficult to manipulate; they can cause persisting infections or show great antigenic variation. A range of new approaches to improve selected immune responses, such as immunization with DNA or chimeric live vectors, viral or bacterial, are under intense scrutiny, as well as genomic analysis of the agent.</abstract><note>Review</note><subject lang="en"><genre>Index Entries</genre><topic>Vaccines</topic><topic>vaccination</topic><topic>infectious agents</topic><topic>immune responses</topic><topic>emerging diseases</topic></subject><relatedItem type="host"><titleInfo><title>Molecular Biotechnology</title></titleInfo><titleInfo type="abbreviated"><title>Mol Biotechnol</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">2005-03-01</dateIssued><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><subject><genre>Biomedicine</genre><topic>Neurosciences</topic><topic>Neurology</topic></subject><identifier type="ISSN">1073-6085</identifier><identifier type="eISSN">1559-0305</identifier><identifier type="JournalID">12033</identifier><identifier type="IssueArticleCount">10</identifier><identifier type="VolumeIssueCount">3</identifier><part><date>2005</date><detail type="volume"><number>29</number><caption>vol.</caption></detail><detail type="issue"><number>3</number><caption>no.</caption></detail><extent unit="pages"><start>255</start><end>271</end></extent></part><recordInfo><recordOrigin>Humana Press Inc., 2005</recordOrigin></recordInfo></relatedItem><identifier type="istex">55176E01945B709336393E38E36BA1A313B4A8DE</identifier><identifier type="ark">ark:/67375/VQC-94QG2FR8-D</identifier><identifier type="DOI">10.1385/MB:29:3:255</identifier><identifier type="ArticleID">293255</identifier><identifier type="ArticleID">Art293255</identifier><accessCondition type="use and reproduction" contentType="copyright">Humana Press Inc, 2005</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>Humana Press Inc, 2005</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-94QG2FR8-D/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001151 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001151 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:55176E01945B709336393E38E36BA1A313B4A8DE
|texte= Overview of vaccines and vaccination
}}
| This area was generated with Dilib version V0.6.33. |  |